Showing results (1121-1130 of 1,403) with videos related to

Sort By:
Pageof 141
Chest|June 16, 2024
Primary Ciliary Dyskinesia in Adult Bronchiectasis: Data from the German Bronchiectasis Registry PROGNOSISRaphael Ewen, Isabell Pink, Sivagurunathan Sutharsan, et al.
American Journal of Cancer Research|October 12, 2020
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancerDavendra Sohal, Smitha Krishnamurthi, Rita Tohme, et al.
Journal of the American Chemical Society|November 14, 2023
Cucurbit[7]uril Enhances Distance Measurements of Spin-Labeled ProteinsZhimin Yang, Richard A Stein, Maren Pink, et al.
European Journal of Cancer Care|December 7, 2019
Does rehabilitation pose a risk to patients suffering from haemato-oncological diseases? Results of a monocentric, retrospective analysis in GermanyThomas Kiefer, Dorothea Krahl, Thomas Kohlmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2007
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma GroupP Reichardt, O S Nielsen, S Bauer, et al.
The Clinical Journal of Pain|January 19, 2013
Understanding the information and service needs of young adults with chronic pain: perspectives of young adults and their providersJennifer Stinson, Meghan White, Lisa Isaac, et al.
JACC. Case Reports|June 4, 2026
Treatment of Acute M3 ThrombosisBatool H Syed, Kevin Pink, Gurinder K Sunner, et al.
EMBO Molecular Medicine|March 15, 2017
Deletion of <i>F4L</i> (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer modelsKyle G Potts, Chad R Irwin, Nicole A Favis, et al.
ESMO Open|June 29, 2024
Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus reportP Schöffski, R L Jones, M Agulnik, et al.
American Journal of Clinical Dermatology|July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc AnalysisJonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Pageof 141